Emerging Biomarkers for the Early Detection of High-Grade Serous Tubo-Ovarian Cancer.
DNA-based liquid biopsies show promise for screening ovarian cancer widely, though better tests are still needed before they can prevent deaths.
This review of current and emerging HGSOC biomarkers concludes that DNA methylation-based liquid biopsy holds the most promise for population-wide screening, though no existing test has demonstrated mortality reduction. The review highlights the need for multimodal biomarker combinations and diverse-population validation to overcome the persistent sensitivity/specificity limitations that have stymied ovarian cancer early detection.
What the study was
- Study design
- Systematic/narrative review
- Population
- General population / HGSOC early detection candidates
- Category
- Early Detection
- Maturity
- Exploratory
- Journal
- Critical Reviews in Oncology/Hematology
Why it surfaced
Ovarian cancer early detection is a high-unmet-need area; this review synthesizes current biomarker landscape with explicit endorsement of methylation-based liquid biopsy approaches. EARLY_CANCER_DETECTION flag auto-elevates to HIGH. Review design limits evidence strength.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.